BioLineRx Statistics
Total Valuation
BioLineRx has a market cap or net worth of ILS 56.27 million. The enterprise value is 3.85 million.
Market Cap | 56.27M |
Enterprise Value | 3.85M |
Important Dates
The last earnings date was Thursday, August 14, 2025.
Earnings Date | Aug 14, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
BioLineRx has 2.56 billion shares outstanding. The number of shares has increased by 65.34% in one year.
Current Share Class | 2.56B |
Shares Outstanding | 2.56B |
Shares Change (YoY) | +65.34% |
Shares Change (QoQ) | +6.85% |
Owned by Insiders (%) | 0.17% |
Owned by Institutions (%) | 4.58% |
Float | 2.45B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.97 |
PB Ratio | 0.83 |
P/TBV Ratio | 1.73 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.15 |
EV / Sales | 0.07 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -0.05 |
Financial Position
The company has a current ratio of 2.06, with a Debt / Equity ratio of 0.63.
Current Ratio | 2.06 |
Quick Ratio | 1.84 |
Debt / Equity | 0.63 |
Debt / EBITDA | n/a |
Debt / FCF | -0.59 |
Interest Coverage | -1.96 |
Financial Efficiency
Return on equity (ROE) is -45.94% and return on invested capital (ROIC) is -21.26%.
Return on Equity (ROE) | -45.94% |
Return on Assets (ROA) | -15.36% |
Return on Invested Capital (ROIC) | -21.26% |
Return on Capital Employed (ROCE) | -47.69% |
Revenue Per Employee | 2.08M |
Profits Per Employee | -941,238 |
Employee Count | 28 |
Asset Turnover | 0.32 |
Inventory Turnover | 2.16 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -88.36% in the last 52 weeks. The beta is 0.88, so BioLineRx's price volatility has been lower than the market average.
Beta (5Y) | 0.88 |
52-Week Price Change | -88.36% |
50-Day Moving Average | 2.41 |
200-Day Moving Average | 3.26 |
Relative Strength Index (RSI) | 45.68 |
Average Volume (20 Days) | 3,926,007 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioLineRx had revenue of ILS 58.12 million and -26.35 million in losses. Loss per share was -0.01.
Revenue | 58.12M |
Gross Profit | 34.48M |
Operating Income | -44.65M |
Pretax Income | -26.35M |
Net Income | -26.35M |
EBITDA | -36.49M |
EBIT | -44.65M |
Loss Per Share | -0.01 |
Balance Sheet
The company has 94.88 million in cash and 42.46 million in debt, giving a net cash position of 52.41 million or 0.02 per share.
Cash & Cash Equivalents | 94.88M |
Total Debt | 42.46M |
Net Cash | 52.41M |
Net Cash Per Share | 0.02 |
Equity (Book Value) | 67.63M |
Book Value Per Share | 0.03 |
Working Capital | 55.20M |
Cash Flow
In the last 12 months, operating cash flow was -71.44 million and capital expenditures 20,216, giving a free cash flow of -71.42 million.
Operating Cash Flow | -71.44M |
Capital Expenditures | 20,216 |
Free Cash Flow | -71.42M |
FCF Per Share | -0.03 |
Margins
Gross margin is 59.32%, with operating and profit margins of -76.81% and -45.34%.
Gross Margin | 59.32% |
Operating Margin | -76.81% |
Pretax Margin | -45.34% |
Profit Margin | -45.34% |
EBITDA Margin | -62.78% |
EBIT Margin | -76.81% |
FCF Margin | n/a |
Dividends & Yields
BioLineRx does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -65.34% |
Shareholder Yield | n/a |
Earnings Yield | -46.84% |
FCF Yield | -126.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on June 7, 2015. It was a reverse split with a ratio of 0.1.
Last Split Date | Jun 7, 2015 |
Split Type | Reverse |
Split Ratio | 0.1 |
Scores
BioLineRx has an Altman Z-Score of -12.27 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -12.27 |
Piotroski F-Score | 3 |